Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), eFFECTOR Therapeutics (EFTR – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report).
Crispr Therapeutics AG (CRSP)
In a report issued on December 8, Salim Syed from Mizuho Securities assigned a Buy rating to Crispr Therapeutics AG, with a price target of $82.00. The company’s shares closed last Tuesday at $58.12.
According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $80.00 average price target, which is a 32.2% upside from current levels. In a report issued on December 4, JMP Securities also maintained a Buy rating on the stock with a $74.00 price target.
See today’s best-performing stocks on TipRanks >>
eFFECTOR Therapeutics (EFTR)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on eFFECTOR Therapeutics on December 8 and set a price target of $7.00. The company’s shares closed last Tuesday at $0.40, close to its 52-week low of $0.34.
According to TipRanks.com, Goldstein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on eFFECTOR Therapeutics is a Moderate Buy with an average price target of $6.00.
Arcutis Biotherapeutics (ARQT)
Mizuho Securities analyst Uy Ear maintained a Hold rating on Arcutis Biotherapeutics on December 8 and set a price target of $4.00. The company’s shares closed last Tuesday at $2.06, close to its 52-week low of $1.76.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
Currently, the analyst consensus on Arcutis Biotherapeutics is a Moderate Buy with an average price target of $9.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRSP:
